

Cited in: *EMBASE/Excerpta Medica, Oncology Information Service, Elsevier BIOBASE/Current Awareness in Biological Sciences; Current Contents/Clinical Medicine; SciSearch, Index Medicus/MEDLINE. Also covered in the abstract and citation database SCOPUS®. Full text available on ScienceDirect®.*

*Original Research Articles*

- Interest in lifestyle advice at lung cancer screening: Determinants and preferences**  
C. Stevens, S.G. Smith, S.L. Quaife, C. Vrinten, J. Waller, R.J. Beeken (UK) 1
- Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation**  
X. Yan, H. Wang, P. Li, G. Zhang, M. Zhang, J. Yang, X. Zhang, X. Zheng, Z. Ma (China) 6
- Prognostic impact of microscopic vessel invasion and visceral pleural invasion and their correlations with epithelial-mesenchymal transition, cancer stemness, and treatment failure in lung adenocarcinoma**  
S. Neri, T. Menju, T. Sowa, Y. Yutaka, D. Nakajima, M. Hamaji, A. Ohsumi, T.F. Chen-Yoshikawa, T. Sato, M. Sonobe, A. Yoshizawa, H. Haga, H. Date (Japan) 13
- Exploration of germline variants responsible for adverse events of crizotinib in *anaplastic lymphoma kinase*-positive non-small cell lung cancer by target-gene panel sequencing**  
H. Mizugaki, A. Hamada, T. Shibata, F. Hosoda, H. Nakamura, Y. Okuma, T. Shukuya, S. Umemura, A. Horiike, T. Fukui, Y. Kogure, H. Daga, Y. Urata, K. Yamada, S. Saeki, Y. Fujisaka, Y. Nakamura, M. Sato, T. Yoshida, T. Hotta, S. Oizumi, Y. Fujiwara, Y. Ohe, Y. Fujiwara (Japan) 20
- Co-expression of IDO1 and PD-L1 in lung squamous cell carcinoma: Potential targets of novel combination therapy**  
K. Takada, K. Kohashi, M. Shimokawa, A. Haro, A. Osoegawa, T. Tagawa, T. Seto, Y. Oda, Y. Maehara (Japan) 26
- Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring *EGFR* T790M**  
S. Zhao, X. Li, C. Zhao, T. Jiang, Y. Jia, J. Shi, Y. He, J. Li, F. Zhou, G. Gao, W. Li, X. Chen, C. Su, S. Ren, C. Zhou (PR China) 33
- Static lung hyperinflation is an independent risk factor for lung cancer in patients with chronic obstructive pulmonary disease**  
E. Zamarrón, E. Prats, E. Tejero, P. Pardo, R. Galera, R. Casitas, E. Martínez-Cerón, D. Romera, A. Jaureguizar, F. García-Río (Spain) 40
- Prognostic value of preoperative exercise capacity in patients undergoing thoracoscopic lobectomy for non-small cell lung cancer**  
K. Hamada, M. Irie, Y. Fujino, M. Hyodo, T. Hanagiri (Japan) 47
- Nut and peanut butter consumption and the risk of lung cancer and its subtypes: A prospective cohort study**  
L. Nieuwenhuis, P.A. van den Brandt (the Netherlands) 57
- Patient-reported outcomes (PROs) in lung cancer: Experiences from a nationwide feasibility study**  
M.M. Brønserud, M. Iachina, A. Green, M. Groenvold, L. Dørflinger, E. Jakobsen (Denmark) 67

(Contents continued overleaf)



<b>Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer</b> L. Horn, J. Bauml, P.M. Forde, K.L. Davis, N.J. Myall, M. Sasane, A. Dalal, K. Culver, A.J. Wozniak, C.S. Baik, A. Mutebi, P. Zhang, H.A. Wakelee, B.E. Johnson (USA)	74
<b>Clinical characteristics and medical service utilization of lung cancer in China, 2005-2014: Overall design and results from a multicenter retrospective epidemiologic survey</b> J.-F. Shi, L. Wang, N. Wu, J.-L. Li, Z.-G. Hui, S.-M. Liu, B.-Y. Yang, S.-G. Gao, J.-S. Ren, H.-Y. Huang, J. Zhu, C.-C. Liu, J.-H. Fan, S.-J. Zhao, P.-Y. Xing, Y. Zhang, N. Li, W.-D. Lei, D.-B. Wang, Y.-C. Huang, X.-Z. Liao, X.-J. Xing, L.-B. Du, L. Yang, Y.-Q. Liu, Y.-Z. Zhang, K. Zhang, Y.-L. Qiao, J. He, M. Dai (China)	91
<b>Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study</b> S.M. Gadgeel, R.V. Lukas, J. Goldschmidt, P. Conkling (USA), K. Park (Republic of Korea), D. Cortinovis, F. de Marinis (Italy), A. Rittmeyer (Germany), J.D. Patel (USA), J. von Pawel (Germany), C. O'Hear, C. Lai, S. Hu, M. Ballinger, A. Sandler, M. Gandhi, L. Fehrenbacher (USA)	105
<b>The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer</b> K. Ito, S. Miura, T. Sakaguchi, K. Murotani, N. Horita, H. Akamatsu, K. Uemura, S. Morita, N. Yamamoto (Japan)	113
<b>Chest radiography surveillance for lung cancer: Results from a National Health Insurance database in South Korea</b> H.J. Koo, C.-M. Choi, S. Park, H.N. Lee, D.K. Oh, W.-J. Ji, S. Kim, M.Y. Kim (Republic of Korea)	120
<b>Stereotactic ablative radiotherapy (SABR) in early stage non-small cell lung cancer: Comparing survival outcomes in adenocarcinoma and squamous cell carcinoma</b> S. Abel, S. Hasan, R. White, L. Schumacher, G. Finley, A. Colonias, R.E. Wegner (United States)	127
<b>Anti-tumoral activity of the human-specific duplicated form of <math>\alpha 7</math>-nicotinic receptor subunit in tobacco-induced lung cancer progression</b> J.L. Cedillo, A. Bordas, F. Arnalich, I. Esteban-Rodríguez, C. Martín-Sánchez, M. Extremera, G. Atienza, J.J. Rios, R.L. Arribas, C. Montiel (Spain)	134
<b>Factors influencing recurrence following anatomic lung resection for clinical stage I non-small cell lung cancer</b> M.J. Schuchert, D.P. Normolle, O. Awais, A. Pennathur, D.O. Wilson, J.D. Luketich, R.J. Landreneau (USA)	145
<b>Genetic alterations of driver genes as independent prognostic factors for disease-free survival in patients with resected non-small cell lung cancer</b> A. Ono, M. Isaka, M. Serizawa, K. Omae, H. Kojima, K. Nakashima, S. Omori, K. Wakuda, H. Kenmotsu, T. Naito, H. Murakami, K. Urakami, T. Nagashima, T. Sugino, M. Kusuhara, T. Takahashi, K. Yamaguchi, Y. Ohde (Japan)	152
<i>Case Reports</i>	
<b>Complete tumor response of a locally advanced lung large-cell neuroendocrine carcinoma after palliative thoracic radiotherapy and immunotherapy with nivolumab</b> C. Mauclet, F. Duplaquet, L. Pirard, B. Rondelet, M. Dupont, C. Pop-Stanciu, T. Vander Borgh, M. Rimmelink, N. D'Haene, S. Lambin, M. Wanet, V. Remouchamps, S. Ocak (Belgium)	53
<b>Case report: Crizotinib is effective in a patient with ROS1-rearranged pulmonary inflammatory myofibroblastic tumor</b> S. Mai, G. Xiong, D. Diao, W. Wang, Y. Zhou, R. Cai (China)	101